Laboratoires Vivacy in the news

PharmaResearch and Laboratoires VIVACY have formed a strategic partnership to distribute the polynucleotide-based medical device Rejuran across 22 European countries, leveraging VIVACY's established network to expand market presence.

Laboratoires Vivacy is expanding its global operations.

Vivacy struggles to recruit staff near the Swiss border but is improving hiring through enhanced HR efforts and innovative recruitment methods.

Laboratoires Vivacy expanded its ArchParc site to meet rising demand in the medical and intimate aesthetics market.

Vivacy has over 100 million euros in revenue, invests heavily in R&D, and employs 250 people across multiple sites.

Vivacy is expanding globally with subsidiaries and targeting China and the U.S. markets while preparing for costly new European medical device regulations.

Laboratoires Vivacy installed a 2,600 m2 solar panel roof producing 360 MWh annually at their Archamps site.

Laboratoires Vivacy partners with Madame Figaro to launch a hydrating skincare product enhancing skin plumpness and radiance, available in France from August 25.

Vivacy, acquired by Bridgepoint, plans to triple its size by 2028 with 25 million euros in investments and recruitment.

Waldemar Kita sold Vivacy in 2022, remains co-owner of Valljet, and is linked to the Panama Papers.

Waldemar Kita sold his injectable dermatology company Vivacy for around 900 million euros to Bridgepoint.

Laboratoires Vivacy was sold to Bridgepoint for about 900 million euros, near the owners' expected valuation.

ArchParc has helped biomedical companies like Laboratoires Vivacy expand, with Vivacy moving to a large production site and employing 200 staff.

Bridgepoint is the only bidder to buy Vivacy, a hyaluronic acid product lab owned by Waldemar Kita, with Rothschild & Co managing the sale process.

TA Associates is reportedly considering selling Laboratoires Vivacy, an injectable medical devices brand, with a potential valuation of €1 billion.

TA Associates is planning to sell Laboratoires Vivacy, a French injectable dermal filler company, with a potential valuation of around $1 billion.

Laboratoires Vivacy, a French injectable cosmetics firm, is up for sale with TA Associates seeking a deal valuing it near 1 billion euros.

Vivacy is achieving double-digit annual growth, but detailed article content is behind a subscription paywall.

Vivacy is expanding production and R&D to strengthen its leadership in hyaluronic acid injectables and dermocosmetics, while growing internationally and rejecting acquisition offers.

Waldemar Kita is reportedly seeking to sell Vivacy, his hyaluronic acid product lab, with offers between 700-850 million euros but aiming for 1 billion euros.